Bayer

Diversified pharma

BAYN · Xetra · Germany

Public Market Listing

BAYNXetra

Xetra primary exchange listing

Live quotes, historical charts, and market capitalization for Bayer are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(21 total)
21Total Assets
12Approved
3Phase 3 / Filed
6Phase 1–2 / Early
19Diseases
Quick filter:
Showing 21 of 21 assets
Target & Modality
Acarbose(Precose / Glucobay)
Approved
Alpha-glucosidaseSmall molecule
Type 2 Diabetes
Acoramidis(Attruby)
Approved
Transthyretin (TTR)Small molecule
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy
Aficamten(Myqorzo)
Approved
Cardiac myosin (inhibitor)Small molecule
Hypertrophic Cardiomyopathy
Approved
VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Finerenone(Kerendia)
Approved
Mineralocorticoid receptorSmall molecule
Heart FailureChronic Kidney Disease
Approved
Interferon beta receptor (type I IFN signaling) · Type I interferon receptorBiologic (subtype unspecified)
Multiple Sclerosis
Approved
TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Small molecule
Non-Small Cell Lung CancerSolid Tumors
Approved
L-type calcium channels (Cav1.2)Small molecule
Subarachnoid Hemorrhage
Approved
Multi-kinase inhibitor (VEGFR/PDGFR/KIT)Small molecule
Hepatocellular CarcinomaColorectal CancerGastrointestinal Stromal Tumor
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Riociguat(Adempas)
Approved
Soluble guanylate cyclaseSmall molecule
Pulmonary Arterial Hypertension
Sevabertinib(Hyrnuo)
Approved
EGFR/HER2Small molecule
Non-Small Cell Lung Cancer
Vericiguat(Verquvo)
Approved
Soluble guanylate cyclaseSmall molecule
Heart Failure
Miglitol(Glyset)No recent activity
US approval withdrawn
Alpha-glucosidaseSmall molecule
Type 2 Diabetes
Phase 3
Midbrain dopaminergic neuronsCell therapy
Parkinson's Disease
MolidustatNo recent activity
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease

Discontinued programmes (5)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MosliciguatPhase 2Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2026-12 · NCT07333183 · CT.gov ↗
What to watch
2027 (2)
April 2027 (1)
Finerenone · KerendiaPhase 3Chronic Kidney Disease, Proteinuria
Est. primary completion 2027-04-10 · NCT05196035 · CT.gov ↗
What to watch
October 2027 (1)
Sevabertinib · HyrnuoPhase 3Advanced Non-small Cell Lung Cancer, HER2 Mutation
Est. primary completion 2027-10-28 · NCT06452277 · CT.gov ↗
What to watch
2028 (5)
April 2028 (2)
Acoramidis · AttrubyPhase 3Amyloid Cardiomyopathy, Transthyretin-Related
Est. primary completion 2028-04-15 · NCT04988386 · CT.gov ↗
What to watch
RegorafenibPhase 2Solid Malignant Tumors
Est. primary completion 2028-04-27 · NCT06246643 · CT.gov ↗
What to watch
August 2028 (1)
Finerenone · KerendiaPhase 3Chronic Kidney Disease, Proteinuria, Children
Est. primary completion 2028-08-07 · NCT05457283 · CT.gov ↗
What to watch
October 2028 (1)
Bemdaneprocel (MSK-DA01)Phase 3Parkinsons Disease (PD)
Est. primary completion 2028-10 · NCT06944522 · CT.gov ↗
What to watch
December 2028 (1)
Sevabertinib · HyrnuoPhase 1/2Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Est. primary completion 2028-12-01 · NCT05099172 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
MosliciguatPhase 3Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Est. primary completion 2029-01-28 · NCT07816185 · CT.gov ↗
What to watch
February 2029 (1)
Sevabertinib · HyrnuoPhase 2Advanced Solid Tumors, HER2 Mutation
Est. primary completion 2029-02-02 · NCT06760819 · CT.gov ↗
What to watch
March 2029 (1)
Aficamten · MyqorzoPhase 2/3Symptomatic Hypertrophic Cardiomyopathy (HCM)
Est. primary completion 2029-03 · NCT04848506 · CT.gov ↗
What to watch
June 2029 (1)
BAY 3713372Phase 1/2MTAP-deleted Solid Tumors
Est. primary completion 2029-06-18 · NCT06914128 · CT.gov ↗
What to watch
August 2029 (1)
Vericiguat · VerquvoPhase 2/3Heart Failure, Left Ventricular Systolic Dysfunction
Est. primary completion 2029-08-20 · NCT05714085 · CT.gov ↗
What to watch
November 2029 (1)
Finerenone · KerendiaPhase 3Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Est. primary completion 2029-11-30 · NCT07188805 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Aficamten · MyqorzoPhase 2/3Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2030-01 · NCT06412666 · CT.gov ↗
What to watch
December 2030 (1)
Finerenone · KerendiaPhase 3Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Est. primary completion 2030-12-30 · NCT07192952 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Acoramidis · AttrubyPhase 3Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Est. primary completion 2031-10 · NCT06563895 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Acoramidis · AttrubyPhase 3Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related …
Est. primary completion 2037-11 · NCT07116473 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(15)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 October 2026Filing acceptedFinerenoneFDA accepts Bayer's sNDA for finerenone (Kerendia) in adults with chronic kidney disease without diabetes (announced 2026-10-08)
US, FDA · Bayer · Source ↗
17 September 2026ApprovalFinerenoneFDA approves Kerendia for CKD associated with type 1 diabetes
US, FDA · Bayer · Source ↗
9 September 2026ApprovalSevabertinibFDA grants accelerated approval to Hyrnuo as a first-line treatment
US, FDA · Bayer · Source ↗
8 September 2026Topline resultMosliciguatPhase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint
Roivant Sciences Ltd. · Source ↗
5 August 2026WithdrawalIloprostFDA withdraws approval of NDA 021779 (Federal Register 2026-13616)
US, FDA · Source ↗
August 2026ApprovalRiociguatFDA updates Boxed Warning on Adempas (NDA204819)
US, FDA · FDA · Source ↗
5 May 2026Topline resultAficamtenACACIA-HCM Phase 3 of aficamten in non-obstructive HCM met both dual primary endpoints
Cytokinetics · Source ↗
May 2026Priority reviewFinerenoneFDA grants Priority Review for finerenone in CKD with type 1 diabetes
US, FDA · Bayer · Source ↗
2 April 2026ApprovalAfliberceptFDA approves EYLEA HD dosing intervals up to every 20 weeks
US, FDA · Source ↗
April 2026FDA action dateAfliberceptFDA target action date for EYLEA HD prefilled syringe
US, FDA · Source ↗
16 March 2026Topline resultFinerenoneFIND-CKD Phase III meets primary endpoint
16 January 2026ApprovalAfliberceptEylea 8 mg approved in the EU for macular edema following RVO
EU, EMA · Source ↗

The 12 most recent of 15 past events are shown.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$15.7B$1.7B$6.6B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$51.7B$6.5B$7.8B$4.1Breport ↗

Bayer reported revenue of $51,661.2M, up 2.4% YoY, R&D spend of $6,539.41M, down 2.7% YoY, cash and equivalents of $7,842.83M, and a quarterly net burn of $4,103.42M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$50.4B$6.7B$6.4B$2.8Breport ↗
2023-FY$51.5B$5.8B—$3.2Breport ↗
2022-FY$53.5B$6.9B——report ↗
2021-FY$52.2B$6.4B——report ↗